Cystinosis
A rare inherited metabolic disorder in which the amino acid cystine accumulates in cells throughout the body, most critically damaging the kidneys, eyes, and other organs over time.
- Confirmed by white blood cell cystine testing
- Approved cysteamine therapy slows progression
- Kidney transplant available for end-stage disease
- Inheritance
- Autosomal recessive
- Cause
- CTNS gene mutation / cystine accumulation
- Typical Onset
- Infancy (nephropathic form)
- Advanced Therapies
- Cysteamine therapy, kidney transplant
Condition Overview
Cystinosis is a rare inherited disorder in which the amino acid cystine builds up inside lysosomes throughout the body because of a defect in the protein that normally transports it out of these cell structures. Over time, this accumulation damages tissues, most prominently the kidneys, where it leads to a pattern of dysfunction called renal Fanconi syndrome and, without treatment, progressive kidney failure.
The most common and severe form, infantile nephropathic cystinosis, typically presents in the first year of life with poor growth, excessive thirst and urination, and laboratory evidence of Fanconi syndrome. Cystine accumulation also affects the eyes, thyroid, muscles, and other organs as children get older, even when kidney function is supported by treatment or transplant.
Because an oral medication can slow disease progression substantially when started early and taken consistently, timely diagnosis and lifelong adherence to therapy are central to long-term outcomes in cystinosis.
Types and Subtypes
Cystinosis is generally divided into three forms based on severity and age of onset.
Symptoms and Signs
Symptoms in nephropathic cystinosis reflect both kidney dysfunction and broader organ involvement that emerges over time.
Causes and Risk Factors
Cystinosis is caused entirely by an inherited gene change affecting how cells transport cystine.
Diagnosis and Investigations
Diagnosis combines recognition of Fanconi syndrome with specific cystine and genetic testing.
Disease Course and Risk Stratification
Cystinosis does not use a tumor staging system. Disease severity is generally tracked by kidney function stage and degree of cystine accumulation, which guides treatment intensity and monitoring.
Standard Treatment Options
Treatment combines disease-specific cystine-depleting therapy with supportive management of kidney and metabolic complications.
Advanced and Emerging Therapies
Beyond standard cysteamine therapy, several approaches aim to improve adherence and explore curative strategies.
Precision Medicine
Extended-release cysteamine formulations
Longer-acting oral formulations reduce dosing frequency, helping improve adherence to lifelong therapy.
Cellular Therapy
Investigational stem cell-based gene therapy
Early clinical research is evaluating autologous stem cell gene therapy aiming to correct the CTNS defect at the cellular level.
Transplant
Kidney transplantation
An established option for end-stage kidney disease; the transplanted kidney is not affected by the underlying gene defect, though systemic cysteamine therapy must continue.
Biomarkers & Precision Medicine
Cystine level monitoring is central to both diagnosis and ongoing treatment adjustment in cystinosis.
When to Seek 2nd Opinion
Specialist nephrology and metabolic input can meaningfully affect long-term outcomes in cystinosis.
Clinical Trials and Research
Prognosis & Outcomes
Outcomes in cystinosis have improved substantially with consistent cysteamine therapy, though lifelong adherence and monitoring remain important.
Supportive Care
Comprehensive supportive care addresses the wide-ranging effects of cystinosis beyond the kidneys.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by cystinosis access specialist nephrology and metabolic review of test results, coordinate second opinions on treatment adherence and transplant planning, and connect with centers experienced in cystinosis care and emerging therapies.
Get a free case reviewFrequently Asked Questions
Cystinosis is a rare inherited disorder in which the amino acid cystine accumulates inside cells due to a defective transporter protein, most critically damaging the kidneys but also affecting the eyes and other organs over time.
Cystinosis is caused by mutations in the CTNS gene, inherited in an autosomal recessive pattern, meaning a child must inherit an altered copy from each parent.
The infantile nephropathic form typically presents with poor growth, excessive thirst and urination, and laboratory evidence of Fanconi syndrome in the first year of life.
Diagnosis is confirmed by measuring elevated cystine levels in white blood cells, supported by CTNS gene sequencing and characteristic findings on eye examination.
Yes. Oral cysteamine therapy reduces cystine accumulation and slows progression of kidney and other organ damage when started early and taken consistently; cysteamine eye drops address corneal crystals separately.
No. While kidney involvement is usually the most significant early issue, cystine accumulation also affects the eyes, muscles, thyroid, and other organs over time, even after kidney transplant.
A kidney transplant addresses kidney failure but does not cure the underlying genetic condition. Cysteamine therapy must continue after transplant to protect other organs from ongoing cystine accumulation.
Yes, cystine crystals can accumulate in the cornea, causing light sensitivity, which is managed with cysteamine eye drops and regular ophthalmologic follow-up.
Ocular (non-nephropathic) cystinosis affects mainly the eyes without significant kidney involvement, while juvenile cystinosis has slower-progressing kidney involvement than the infantile form.
Yes. CancerFax can help families review nephrology and genetic test results, coordinate second opinions on treatment adherence and transplant planning, and connect with specialist centers experienced in cystinosis care.
Get Expert Guidance for Cystinosis
Send kidney function and genetic test results for specialist review, or request a second opinion on treatment planning.